Medicinal chemistry-Anticancer agents

Various anticancer classes along with their detailed mechanism of action and medicinal chemistry

1. AnticAncer Agents
Prepared by
Mr. Dharmendrasinh A Baria
Assistant professor
Department of Pharmaceutical Chemistry
Smt. S. M. Shah Pharmacy college, Amsaran
1

2. Cancer* is a term used for diseases in which abnormal cells divide without control
and are able to invade other tissues. Cancer cells can spread to other parts of the
body through the blood and lymph systems, this process is called metastasis.
Characteristics of Cancer Cells:
•Cancer involves the development and reproduction of abnormal cells
•Cancer cells are usually nonfunctional
•Cancer cell growth is not subject to normal body control mechanisms
•Cancer cells eventually metastasize to other organs via the circulatory and
lymphatic systems.
(*National Cancer Institute, NCI)
2By: Dharmendrasinh Baria

3. Types of Tumors :
Benign: non cancerous and not an immediate threat to life, even though
treatment eventually may be required for health.
Malignant : tending to worsen and cause death, invasive and metastasis
3By: Dharmendrasinh Baria

4. •Categorized based on the functions/locations of the cells from which they
originate:
1.Carcinoma - skin or in tissues that line or cover internal organs. E.g., Epithelial
cells. 80-90% reported cancer cases are carcinomas.
2.Sarcoma - bone, cartilage, fat, muscle, blood vessels, or other connective or
supportive tissue.
3.Leukemia - White blood cells and their precursor cells such as the bone marrow
cells, causes large numbers of abnormal blood cells to be produced and enter
the blood.
4.Lymphoma - cells of the immune system that affects lymphatic system.
5.Myeloma - B-cells that produce antibodies- spreads through lymphatic system.
6.Central nervous system cancers - cancers that begin in the tissues of the
brain and spinal cord.
4By: Dharmendrasinh Baria

5. •Antineoplastic agents are drugs used for the treatment of cancer.
•The fraction of tumor cells that are in the replicative cycle (“Growth factor”),
influence their susceptibility to most cancer chemotherapeutic agent.
•Rapidly dividing cells are generally more sensitive to anticancer drugs, whereas
non proliferating cells [those in G0 phase] usually survive the toxic effect of these
drugs.
•Normal cells and tumor cells go through growth cycle. However , normal and
neoplastic tissue may differ only in the number of cells that are in the various
stages in the cycle. Chemotherapeutic agents that are effective only in replicating
cells.
5By: Dharmendrasinh Baria

6. 6By: Dharmendrasinh Baria

7. 7By: Dharmendrasinh Baria

8. 1)Based on site of action
2)Chemical classification
1. Based on site of action
I.Phase specific agents: These drugs acts at particular phase of cell cycle
and more effective in proliferating cells.
a)G1 – Vincristine
b)S–Methotrexate, Cytarabine, 6-TG, 6-MP, 5-FU, Daunorubicin, Doxorubicin
c)G2 – Daunorubicin, Bleomycin
d)M – Vincristine, Vinblastne, Paclitaxel etc.
8By: Dharmendrasinh Baria

9. II.Phase non specific agents: Nitrogen Mustards, Cyclphosphamide,
Chlorambucil, Carmustine, Dacarbazine, Busulfan, L-Asparginase, Cisplatin,
Procarbazine and Actinomycin D etc.
III.These drugs are specifically effective against proliferating cells but they are not
phase specific: e.g. Fluorouracil, cyclophosphamide, Dactinomycin.
9By: Dharmendrasinh Baria

10. 2. Chemical classification
a.Alkylating Agents
1. Nitrogen mustards – Mechlorethamine (Mustine HCL), Cyclophosphamide,
Ifosfamide, Melphalan, Chlorambucil
Chroambucil
Melphalan
Cyclophosphamide
Ifosfamide
Mechlorethamine
10By: Dharmendrasinh Baria

11. 2.Ethylenimine - Thio-TEPA, hexamethylmelamine (Altretamine)
3. Alkyl sulfonate – Busulfan
4. Nitrosoureas – Carmustine, Lomustine, Streptozocin
Triethylene melamineThiotepa
Busulphan
Carmustine
Streptozocin
Lomustine
11By: Dharmendrasinh Baria

12. 5. Triazines - Procarbazine, Dacarbazine, Temozolomide
b. Platinum coordination complexes – Cisplatin, Carboplatin,Oxaliplatin
Procarbazine
Dacarbazine
Temozolomide
12By: Dharmendrasinh Baria

13. c. Antimetabolites –
I.Pyrimidine analogs – 5-Fluorouracil , Cytarabine (cytosine arabinoside),
Capecitabine, Gemcitabine
13By: Dharmendrasinh Baria

14. II.Purine analogs – 6-Mercaptopurine, 6-Thioguanine, Azathioprine, Fludarabine,
Cladribine, Pentostatin
14By: Dharmendrasinh Baria

15. III.Folic acid analogues – Methotrexate, Pemetrexed
15By: Dharmendrasinh Baria

16. d. Anticancer Antibiotics – Actinomycin-D (Dactinomycin), Bleomycin, mitomycin-
C, anthracyclines (e.g. Doxorubicin, Daunorubicin, Idarubicin, epirubicin, Valrubicin),
Streptozocin
16By: Dharmendrasinh Baria

17. e. Plant products- vincristine, vinblastine, podophyllotoxin, etoposide, camptothecin,
paclitaxal
17By: Dharmendrasinh Baria

18. 18By: Dharmendrasinh Baria

19. f. Protein kinase inhibitors-
g. Miscellaneous –L-Asparaginase, Arsenic trioxide
Hydroxyurea Tretinoin
19By: Dharmendrasinh Baria

20. h. Hormonal drugs –
1. Glucocorticoids – Prednisolone and others
Prednisolone
2. Estrogens – Fosfestrol, Ethinylestradiol
Fosfestrol Ethinylestradiol
20By: Dharmendrasinh Baria

21. 21By: Dharmendrasinh Baria

22. 22By: Dharmendrasinh Baria

23. 23By: Dharmendrasinh Baria

24. 9. Progestins –
Hydroxyprogesterone acetate, etc
10. GnRH antagonists – Cetorelix, Ganirelix, Abarelix
24By: Dharmendrasinh Baria

25. 25By: Dharmendrasinh Baria

26. •The alkylating agents are a class of drugs that are capable of forming covalent
bonds with important biomolecules.
•The major targets of drug action are nucleophilic groups present on DNA
(especially the 7-position of guanine); however, proteins and RNA among
others may also be alkylated.
•There are several potential nucleophilic sites on DNA, which are susceptible to
electrophilic attack by an alkylating agent (N-2, N-3, and N-7 of guanine, N-1,
N-3, and N-7 of adenine, 0–6 of thymine, N-3 of cytosine).
•Potential mechanisms of cell death include activation of apoptosis caused by
p53 activation and disruption of the template function of DNA.
•The most important of these for many alkylating agents is the N-7 position of
guanine whose nucleophilicity may be enhanced by adjacent guanine residues.
26By: Dharmendrasinh Baria

27. •Additionally, alkylation has been proposed to result
in altered base pairing away from the normal G-C:
A-T hydrogen bonds because of alterations in
tautomerization.
•The alkylation also leads to increased acidity of the
N-1 nitrogen reducing the pK from 9 to 7 to 8 giving
rise to a zwitter ionic form that may also mispair.
•For those agents that possess two reactive
functionalities, both inter strand and intra strand
cross-linking becomes possible. When inter strand
links occur, separation of the two strands during
replication is prevented and therefore replication is
blocked.
AT
C
G
C
G
G
AT
G C
27By: Dharmendrasinh Baria

28. 28By: Dharmendrasinh Baria

29. 1. Nitrogen mustard
Developed from mustard war gases of Word War I which were highly reactive
vesicants.
First chemicals used for cancer Rx.
Not cell cycle specific, but still more active in dividing tissues.
"Radiomimetic" -- action on DNA resembles radiation.
The nucleophile may be-
• SH of protein
•-N of protein, DNA base
•=O of DNA base
29By: Dharmendrasinh Baria

30. •At physiological PH, aliphatic mustard hydrochlorie converted into aziridium ion
that reacts with nucleophile.
•These agents acts by alkylating the N7 of guanine in DNA which leads to
30By: Dharmendrasinh Baria

31. a)Mechlorethamine: 2,2 dichloro-N-methyl diethylamine hydrochloride
•Given by i.v administration of freshly prepared solution because gradual
degradation of the aziridium ion by interaction with water.
•Uses:
Hodkin’s disease
Lymphomas
Thrombocytopenia
Leucopenia
•Important candidate of well known MOPP regimen.
M- Mechlorethamine, O- Oncovin, P-Procarbazine, P- Prednisone
31By: Dharmendrasinh Baria

32. b) Chlorambucil: p- (di (2-chloroethyl) amino) phenyl butyric acid
•Quite stable compound to aziridium ion so it can be given orally.
•Uses: Especially in
–Chronic lumphocytic leukemia
–Primary macroglobulinemia
–Lymphosarcoma
–Hodkin’s disease
c) Melphalan: 4-[Bis(2-chloroethyl)amino]-L-phenylalanine
•Uses:
•Multiple myeloma
•Breast cáncer
•Ovarian cancer
32By: Dharmendrasinh Baria

33. d) Cyclophosphamide- (RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-
2-amine-2-oxide
•In these case, aziridinium cation formation is not possible until the electron-
withdrawing function has been altered. In the case of cyclophosphamide, it was
initially believed that the drug could be selectively activated in cancer cells because
they were believed to contain high levels of phosphoramidase enzymes.
•Drug was activated by cytochrome P450 (CYP) isozymes CYP2B6 and CYP3A4/5
to give a carbinolamine that could undergo ring opening to give the aldehyde.
•The ionized phosphoramide is now electron-releasing via induction and allows
aziridinium cation formation to proceed. Acrolein is also formed as a result of this
process, which may itself act as an electrophile that has been associated with
bladder toxicity.
33By: Dharmendrasinh Baria

34. •To decrease the incidence of kidney and bladder toxicity, the sulfhydryl (-SH)
containing agent mesna may be administered and functions to react with the
electrophilic species that may be present in the kidney.
•The sulfonic acid functionality serves to help concentrate the material in the urine,
and the nucleophilic sulfhydryl group may react with the carbinolamine, aziridinium
cation, the chloro substituents of cyclophosphamide, or via conjugate addition with
acrolein.
•This inactivation and detoxification may also be accomplished by other thiol-
containing proteins such as glutathione. Increased levels of these proteins may
occur as cancer cells become resistant to these alkylating agents.
•Uses - Multiple myeloma
–Chronic lymhatic leukemia
–Acute leukemia
–Acute lymphoblastic leukemia
34By: Dharmendrasinh Baria

35. 35By: Dharmendrasinh Baria

36. e) Mitomycin-C
•Antibiotic obtained from the cultures of s. cespitosus.
Reduced enzymatically to its
semiquinone radical
Vinylogous carbinolamine system is obtained
Stable carbonium ion
Alkylates DNA
36By: Dharmendrasinh Baria

37. 37By: Dharmendrasinh Baria

38. •Alkylation step results from opening of the aziridium ring and also vinylogous
carbinolamine
•Causes cross linking in double helical DNA.
•The 2-amino group of guanine residues are alkylated.
•Uses:
–Breast cancer
–Gastric cancer
–Pancreatic cancer
38By: Dharmendrasinh Baria

39. 2. Ethylenimine - Thio-TEPA, hexamethylmelamine (Altretamine)
Thiotepa- 1,1',1''-phosphorothioyltriaziridine
39By: Dharmendrasinh Baria

40. •Uses:
–Breast cancer
–Ovarian cancer
–Bronchogenic cancer
40By: Dharmendrasinh Baria

41. 3. Alkyl sulfonates
•Busulfan- butane-1,4-diyl dimethanesulfonate
•Busulfan utilizes two sulfonate functionalities as leaving groups separated by a
•four-carbon chain that reacts with DNA to primarily form in- trastrand cross-link
at 5’-GA-3’sequences.
O
OS
SCH
3
O
O
CH
3
O
O
Methansulfonate
Ionic form causes cleavage of
DNA strand
•Uses:
•Chronic granulocytic leukemia
•Bone marrow transplant
41By: Dharmendrasinh Baria

42. 42By: Dharmendrasinh Baria

43. 4. Nitrosoureas (N-alkyl-N-Nitrosourea)
•Unstable in aqueous solution.
•They produce isocyanate and a diazohydroxide upon decomposition.
Nitrosoureas
Isocyanate + Diazohydroxide
Decomposes
yields a diazo species that
decomposes to a reactive carbocation
The carbocation is believed to be the
agent responsible for DNA alkylation.
isocyanate carbamylates
proteins and RNA
43By: Dharmendrasinh Baria

44. 44By: Dharmendrasinh Baria

45. •Carmustine - 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)
•Uses:
•Higher lipophilicity, so higher penetration in BBB. It can be used in cerebral
tumors.
•Hodkin’s disease
•Lymphoma
•Lomustine - N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea (CCNU)
•Uses:
•Primary and metastatic brain tumors.
•Secondary therapy in Hodkin’s disease.
45By: Dharmendrasinh Baria

46. 5. Triazines:
a)Procarbazine- N-Isopropyl-4-[(2-methylhydrazino) methyl] benzamide
•Procarbazine is an antineoplastic agent that was originally developed as a result of
efforts to find new inhibitors of monoamine oxidase. Subsequent screening revealed
antineoplastic activity.
Uses: Hodkin’s disease
b) Dacarbazine- 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
•It was initially thought to act as an inhibitor of purine biosynthesis, but latter was
shown to be an alkylating agent. Activation of the agent occurs through the action of
CYP (isozymes 1A1, 1A2, and 2E1) to give the demethylated product monomethyl
triazenoimidazole carboxamide.
46By: Dharmendrasinh Baria

47. 47By: Dharmendrasinh Baria

48. 48By: Dharmendrasinh Baria

49. •Cisplatin, Carboplatin, Oxaliplatin
•Platinum (II) is considered to be a “soft” electrophile and as a result, its
complexes are subject to attack by “soft” nucleophiles such as thiol groups
found on proteins. This can result in significant protein binding (88%–95%) and
inactivation caused by the presence of thiols in albumin, glutathione, and other
proteins.
•Cisplatin administration is also associated with significant nephrotoxicity and
neurotoxicity that is dose limiting.
49By: Dharmendrasinh Baria

50. 50By: Dharmendrasinh Baria

51. •Antimetabolites are compounds closely related in structure to a cellular
precursor molecule, yet these imposter substances are capable of preventing
the proper use or formation of the normal cellular product.
•These antimetabolites are similar enough in structure in many cases to interact
with the normal cellular process but differ in a manner sufficient to alter the
outcome of that pathway.
•Most antimetabolites are effective cancer chemotherapeutic agents via
interaction with the biosynthesis of nucleic acids. Therefore, several of the
useful drugs used in antimetabolite therapy are purines, pyrimidines, folates,
and related compounds.
•The antimetabolite drugs may exert their effects by several individual
mechanisms involving enzyme inhibition at active, allosteric, or related sites.
51By: Dharmendrasinh Baria

52. •Most of these targeted enzymes and processes are involved in the regulatory
steps of cell division and cell/tissue growth. Often the administered drug is
actually a prodrug form of an antimetabolite and requires activation in vivo to
yield the active inhibitor.
•The administration of many purine and pyrimidine antimetabolites requires the
formation of the nucleoside and finally the corresponding nucleotide for
antimetabolite activity.
•An antimetabolite and its transformation products may inhibit several different
enzymes involved in tissue growth.
•These substances are generally cell cycle specific with activity in the S phase.
•The purine and pyrimidine antimetabolites are often compounds incorporated
into nucleic acids and the nucleic acid polymers (DNA, RNA, etc.).
52By: Dharmendrasinh Baria

53. •The antifolates are compounds designed to interact at cofactor sites for
enzymes involved in the biosynthesis of nucleic acid bases. The biosynthesis of
these nucleic acid bases depend heavily on the availability of folate cofactors,
hence antimetabolites of the folates find utility as antineoplastic agents.
53By: Dharmendrasinh Baria

54. 1.Purine analogues:
•The design of antimetabolites based on purine structure began with isosteric
thiol/sulfhydryl group to replace the 6-hydroxyl group of hypoxanthine and guanine.
•One of the early drug was 6-mercaptopurine (6-MP), the thiol analog of
hypoxanthine. This purine requires bio activation to its ribonucleotide, 6-thioinosinate
(6-MPMP), by the enzyme HGPRT.
•The resulting nucleotide is a potent inhibitor of an early step in basic purine
biosynthesis, the conversion of 5-phosphoribosylpyrophosphate into 5-
phosphoribosylamine.
•The ribose diphosphate and triphosphates of 6-mercaptopurine are active enzyme
inhibitors, and the triphosphate can be incorporated into DNA and RNA to inhibit
chain elongation. However, the major antineoplastic action of 6-MP appears to be
related to the inhibition of purine biosynthesis.
54By: Dharmendrasinh Baria

55. It also inhibits the conversion
of Inosinic acid to adenylic acid
O
NH
N
O
N
N
OP
O
O
O
OH OH
O
N
N
NH
2
N
N
OP
O
O
O
OH OH
2 steps
Inosinic acid
Adenylic acid
55By: Dharmendrasinh Baria

56. Reaction of inosinic acid + aspartate
Adenyl succinic acid
Adenylic acid
Fumaric acid
6-Thioinosinate
6-Thioinosinate
Uses: Acute leukemia
Metabolic degradation of 6-MP by guanase gives 6-thioxanthine.
6-MP 6-Thioxanthine 6-Thiouric acid
Guanase
Xanthine oxidase
Allourinol
It increases potency
& Increases Toxicity
56By: Dharmendrasinh Baria

57. Allopurinol Thiouric acid
Allopurinol:
•It is an adjuvant to chemotherapy because it prevents uric acid formation.
•Kidney toxicity caused be the release of purines from destroyed cancer cells.
Azathioprine
Azathioprine:
•Heterocyclic derivative of 6-MP, azathioprine designed to protect it from catabolic
degradation.
•Not significant better antitumor activity than 6-MP.
•Used as an immunosuppressanant.
57By: Dharmendrasinh Baria

58. 6-Thioguanine (6-TG):
O
NH
N
S
N
N
OP
O
O
O
OH OH
NH
2
NH
N
S
N
N
H
NH
2
6-TG
Monophosphate
Hypoxanthine guanine
phsphoribosyl transferase
Diphosphate
Triphosphate
(Active species)
Enzyme inhibitior
•Thioguanine is also incorporated into RNA & its α-deoxy metabolite is incorporated
in to DNA.
•Uses: Acute leukemia
•ADR: Delayed bone marrow depression, Thrombocytopenia
58By: Dharmendrasinh Baria

59. Vidarabine:
•Adenine arabinoside.
•Obtained from the cultures of s. antibioticus.
•Epimeric with D-ribose at 2’ position.
•Competitive inhibitor of DNA polymerase enzyme
•Also having antiviral acticity.
•Limited use due to susceptibility to enzyme
adenosine deaminase (responsible for resistance)
R
1
=R
2
=H
Vidarabine
R
1
=F, R
2
= HOPO
2
Fludarabine
Inhibits
Pentostatin
Inhibition of the enzyme adenosine
deaminase yielding increased
cellular levels of deoxyadenosine
and deoxyadenosine triphosphate
(dATP)
59By: Dharmendrasinh Baria

60. •2-Chloro-2’-deoxyadenosine (cladarabine): Resistant to deaminase.
•Used to treat hairy cell leukemia.
O
N
N
N
N
OH
OH
NH
2
Cl
Triphosphate
cytidine
kinase
Inhibits enzyme required
for DNA repair
Cladarabine
60By: Dharmendrasinh Baria

61. 2. Pyrimidine analogues:
•5-fluorouracil (5-FU)
•The pyrimidine derivative 5-fluorouracil (5-FU) was designed to block the
conversion of uridine to thymidine.
•The normal biosynthesis of thymidine involves methylation of the 5-position of
the pyrimidine ring of uridine.
•The replacement of the hydrogen at the 5-position of uracil with a fluorine
results in an antimetabolite drug, leading to the formation of a stable covalent
ternary complex composed of 5-FU, thymidylate synthase (TS), and cofactor (a
tetrahydrofolate species).
•Anticancer drugs targeting this enzyme should selectively inhibit the formation of
DNA because thymidine is not a normal component of RNA..
61By: Dharmendrasinh Baria

62. •TS is responsible for the reductive methylation of de- oxyuridine monophosphate
(dUMP) by 5,10-methylenetetrahydrofolate to yield dTMP and dihydrofolate
62By: Dharmendrasinh Baria

63. 63By: Dharmendrasinh Baria

64. •Uses: Management of carcinoma of
- breast
- Colon
- Pancreas
- Rectum
- Keratoses
•Adverse effects:
- GIT-Hemorrhage
- Stomatitis
- Esophagopharyngitis
- Leukopenia
- Diarrhoea
64By: Dharmendrasinh Baria

65. Tetrahydrofluoro derivative of 5-FU (Tegafur):
•Slowly get metabolised to 5-FU.
•Active in clinical cancer.
•Less myelosupressive than 5-FU.
Gemcitabine:
•Gemcitabine is the result of fluorination of the 2’-position of the sugar moiety.
•Gemcitabine is the 2’,2’-difluoro deoxycytidine species and after its anabolism to
diphosphate and triphosphate metabolites, it inhibits ribonucleotide reductase and
competes with 2’-deoxycytidine triphosphate for incorporation into DNA.
•Uses:
•Used with cisplatin for locally advanced metastatic adeno carcinoma of the
pancreas.
•ADR: Myelosupression, Teratogenicity, renal toxicity.
65By: Dharmendrasinh Baria

66. Cytarabine:
•Cytosine arabinoside (ara-C or cytarabine) is simply the arabinose sugar instead of
ribose, and the only difference in structure is the epimeric hydroxyl group at the 2-
position of the pentose sugar.
•This epimeric sugar is similar enough to the natural ribose to allow Ara-C to be
incorporated into DNA, and its mechanism of action may include a slowing of the
DNA chain elongation reaction via DNA polymerase or cellular inefficiencies in DNA
processing or repair after incorporation.
O
OH
OH
OH
N
N
NH
2
O
Monophosphate Diphosphate Triphosphate
Cytosine arabinoside
Cytidylic acid 2'-Deoxycytidylic acid
66By: Dharmendrasinh Baria

67. O
OH
OH
OH
N
N
NH
2
O
O
OH
OH
OH
N
N
O
O
Cytosine arabinoside
Uridine arabinoside
Inactive
Deaminase
•Deaminases causes resistance.
New analogues of cytarabine is cyclocytidine (ancitabine)
•Resistant to deamination by deaminases laeds to better therapeutic index.
•Uses: Acute granulocytic leukemia
67By: Dharmendrasinh Baria

68. •Deaminase inhibitors:
1)Pentostatin: Purine analogue
- 7 membered ring structure
-2’ deoxyformycin
2) EHNA:
- Adenine moiety is modified in the ribose moiety.
- Rationally designed inhibitors
68By: Dharmendrasinh Baria

69. 3. Folate antagonists
69By: Dharmendrasinh Baria

70. •Methotrexate is the classic antimetabolite of folic acid structurally derived by N-
methylation of the para-aminobenzoic acid residue (PABA) and replacement of
a pteridine hydroxyl by the bioisosteric amino group.
•The conversion of -OH to –NH
2
increases the basicity of N-3 and yields greater
enzyme affinity.
•This drug competitively inhibits the binding of the substrate folic acid to the
enzyme DHFR, resulting in reductions in the synthesis of nucleic acid bases,
perhaps most importantly, the conversion of uridylate to thymidylate as
catalyzed by thymidylate synthetase.
•In addition, purine synthesis is inhibited because the N-10-formyl
tetrahydrofolic acid is a formyl donor involved in purine synthesis.
•THFs are cofactors in at least two key steps in the normal biosynthesis of
purines.
70By: Dharmendrasinh Baria

71. •It binds with enzyme so tightly, hence called pseudo-irreversible binding.
•The basis of this binding strength is in the diamino pyrimidine ring, which is
protonated at physiological pH.
Uses:
•Acute lymphocytic keukemia
•Prophylexis in meningeal leukemia
•Choriocarcinoma
•Combination therapy for palliative management of breast cancer and
osteocarcinoma
ADR: Ulcerative stomatitis, Leukopenia, Abdominal distress
71By: Dharmendrasinh Baria

72. •Leucoverin is used in “Rescue therapy” with methotrexate.
•It prevents the lethal effects of methotrexate on normal cells by overcoming the
blockade of tetrahydrofolinic acid production.
•In addition it inhibits the active transport of methotrexate in to cell and
stimulates its efflux.
•Vincristine Increases the cellular uptake of methotrexate.
72By: Dharmendrasinh Baria

73. 1)Dactinomycin (Actinomycin-D)
•Obtained from the cultures of
- Streptomyces parvulus
- S. Chrysamallus
- S. Antibioticus
–They are chromopeptide
–Chromophoric part is substituted 3-phenoxazone-1,9-dicarboxylic acid known
as “actinosin”.
73By: Dharmendrasinh Baria

74. •Mechanism of action:
•Dactinomycin binds noncovalently to double-stranded DNA by partial intercalation
between adjacent guanine-cytosine bases resulting in inhibition of DNA function.
•The structural feature of dactinomycin important for its mechanism of cytotoxicity is
the planar phenoxazone ring, which facilitates intercalation between DNA base
pairs.
•The peptide loops are located within the minor groove and provide for additional
interactions.
•The preference for GpC base pairs is thought to be partly related to the formation
of a hydrogen bond between the 2-amino groups of guanine and the carbonyls of
the L-threonine residues.
•Additional hydrophobic interactions and hydrogen bonds are proposed to form
between the peptide loops and the sugars and base pairs within the minor groove.
74By: Dharmendrasinh Baria

75. •The primary effect of this interaction is the inhibition of DNA-directed RNA
synthesis and specifically RNA polymerase. DNA synthesis may also be
inhibited, and the agent is considered cell cycle specific for the G and S phases.
•Uses:
- Rhabdomyosarcoma
- Wilm’s tumor
- Life saving for women with chromosarcoma resistant to methotrexate
- In combination with vincristine and cyclophosphamide in solid tumors in
children
•ADR: Bone marrow depression, Alopecia, erythema
75By: Dharmendrasinh Baria

76. 2) Anthracyclines:
•Obtained from
–S. Coerulorubidus
–S. Peuceticus
•They have tetracycline ring structures with unusual sugar daunosamine
attached by glycosidic linkage.
76By: Dharmendrasinh Baria

77. •Mechanism of action
77By: Dharmendrasinh Baria

78. Note:
•Tissue with ample of superoxide
Dismutase and glutathione
peroxidase activity are protected.
•Cardiac tissue lacks superoxide
dismutase and catalase enzynes.
•This may be the reason for the
cardiotoxicity of anthra cyclines.
78By: Dharmendrasinh Baria

79. •Uses:
•Acute lymphocytic and granulocytic leukemia
•ADR:
–Bone marrow depression
–Stomatitis
–Alopecia
–Cardiac toxicity
79By: Dharmendrasinh Baria

80. 3) Bleomycin:
•Glycopeptide isolated from Streptomyces verticillus.
•Mixture of closely related compounds with bleomycin A
2
and B
2
which are
available in nature as blue copper chelates.
•M/A: The cytotoxic property of bleomycin are due to fragmentation of DNA.
•It appears to cause scission of DNA by interacting with O
2
and Fe
+2
•It binds with DNA through its amino terminal peptide and the activated complex
generates free radicals that causes DNA breaking.
80By: Dharmendrasinh Baria

81. 4) Streptozocin:
•Isolated from S. achromogens
•It is nitrosoureas derivative of α-Deoxyglucose.
•It is alkylation agent similar in reactivity to other
nitrosoureas.
Uses:
•Indicated only for malignant metastatic islet cell carcinoma of pancreas.
ADR: Renal toxicity, mutagenicity.
81By: Dharmendrasinh Baria

82. 1) Vinca alkaloids
•Binds to the microtubular protein tubulin in a dimeric form
•The drug-tubulin complex adds to the forming end of the
•microtubules to terminate assembly
•Depolymerization of the microtubules occurs
•Resulting in mitotic arrest at metaphase, dissolution of the mitotic spindle, and
interference with chromosome segregation
•CCS agents- M phase
•Uses: Vinblastine- Systemic Hodgkin’s disease, Lymphomas
Vincristine- With prednisone for remission of Acute Leukemia
82By: Dharmendrasinh Baria

83. •M/AM/A
83By: Dharmendrasinh Baria

84. 84By: Dharmendrasinh Baria

85. 2) Taxanes
•First isolated from bark of Western / Pacific
yew (Taxus brevifolia)
•It is used for treatment of lung, ovarian and
breast cancer.
•Taxanes hyper-stabilizes microtubule structure (freez them). Taxanes binds
to the β subunit of tubulin ,the resulting microtubule/ Taxanes complex does
not have the ability to disassemble. This adversely affects cell function
because the shortening and lengthening of microtubules is necessary for
their function.
85By: Dharmendrasinh Baria

86. M/A
86By: Dharmendrasinh Baria

87. 87By: Dharmendrasinh Baria

88. 3) Epipodophyllotoxin:
•From Podophyllum peltatum (May apple)
•Resulting in DNA damage through strand breakage induced by the
formation of a ternary complex of drug, DNA, and enzyme
•Uses: Testicular cancer, small-cell lung carcinoma, Hodgkin lymphoma,
carcinoma of breast, Kaposi’s sarcoma associated with AIDS
88By: Dharmendrasinh Baria

89. •Blocks cells in the late S-G2
phase of the cell cycle
through inhibition of
topoisomerase II
89By: Dharmendrasinh Baria

90. 4) Camptothecin analogues
•First isolated from Camptotheca acuminata (Chinese tree).
•Used in Ovarian cancer, Small cell lung cancer.
90By: Dharmendrasinh Baria

91. f. Protein kinase inhibitors-
•Tyrosine Kinase Inhibitors – Imatinib, geftinib, erlotinib, sorafenib,
sunitinib, lapatinib etc.
•IMATINIB-
•First selectively targeted drug to be introduced Inhibits a specific
tyrosine protein kinase – “Bcr-abl” tyrosine kinase expressed by CML
cells and related receptor tyrosine kinases including PDGF receptor that
is constitutively active in dermatofibrosarcoma protuberans, stem cell
receptor and c-kit receptor active in GIST.
91By: Dharmendrasinh Baria

92. •Very sucessful in chronic phase of CML (remission> 90%) and in
metastatic c-kit (+) GIST . Also indicated in Dermatofibrosarcoma
protuberans.
•Resistance develops mainly due to point mutation in Bcr-Abl tyrosine
kinase.
•metabolised mainly by CYP3A4 , metabolites excreted in faeces through
bile.
•ADR- Abdominal pain, vomitting, fluid retention,periorbital oedema,pleuarl
effusion,myalgia and CHF.
•Dasatinib and Nilotinib are similar drugs used in case of Imatinib
resistance
92By: Dharmendrasinh Baria

93. g. Miscellaneous – L-Asparaginase, Asparaginase, Hydroxurea,
Mitoxantrone
•L-Asparaginase:
•An enzyme isolated from E.Coli.
•Causes catabolic depletion of serum asparagine to aspartic acid
and ammonia resulting in reduced blood glutamine levels and
inhibition of protein synthesis.
•Neoplastic cells require external source of asparagine.
•Treats childhood acute leukemia
•Can cause anaphylactic shock
93By: Dharmendrasinh Baria

94. 94By: Dharmendrasinh Baria

95. •Hydroxyurea-
–An analog of urea
–Inhibits the enzyme ribonucleotide reductase.
–Resulting in the depletion of deoxynucleoside triphosphate pools
–Thereby inhibiting DNA synthesis
–S-phase specific agent
–Treats melanoma and chronic myelogenous leukemia
Adverse effects: Myelosuppression (Minimal), Hypersensitivity,
Hyperglycemia, Hypoalbuminemia
95By: Dharmendrasinh Baria

96. •Mitoxantrone
•Structure resembles the anthracyclines
•Binds to DNA to produce strand breakage
•Inhibits DNA and RNA synthesis
•Treats pediatric and adult acute myelogenous leukemia, non-Hodgkin’s
lymphomas, and breast cancer
•Causes cardiac toxicity
96By: Dharmendrasinh Baria

97. •It involves the manipulation of the endocrine system through exogenous
administration of specific hormones, particularly steroid hormones, or
drugs which inhibit the production or activity of such hormones.
•Because steroid hormones are powerful drivers of gene expression in
certain cancer cells, changing the levels or activity of certain hormones
can cause certain cancers to cease growing, or even undergo cell
death.
97By: Dharmendrasinh Baria

98. 1.Glucocorticoids – Prednisolone and others
•Glucocorticoids such as prednisolone and dexamethasone have
marked inhibitory effects on lymphocyte proliferation.
•Used in the treatment of leukaemias and lymphomas.
•Their ability to lower raised intracranial pressure, and to mitigate some
of the side effects of anticancer drugs, makes them useful as
supportive therapy .
Examples
98By: Dharmendrasinh Baria

99. 2. Estrogens
•Physiological antagonists of androgens.
•Thus used to antagonize the effects of androgens in androgen dependent
prostatic cancer.
• The agonist is occasionally used to treat prostate cancer through
suppression of testosterone production.
•Diethylstilbestrol and ethinyloestradiol are two oestrogens used clinically in
the palliative treatment of androgen-dependent prostatic tumours.
•The latter compound has fewer side effects. These tumours are also treated
with gonadotrophin-releasing hormone analogues
•Oestrogens can be used to recruit resting mammary cancer cells into the
proliferating pool of cells, thus facilitating killing by other cytotoxic drugs
99By: Dharmendrasinh Baria

100. 3. Selective estrogen receptor modulators- Tamoxifen, Toremifene
100By: Dharmendrasinh Baria

101. •Selective estrogen receptor modulator (SERM), have both estrogenic and anti-
estrogenic effects on various tissues
•Binds to estrogen receptors (ER) and induces conformational changes in the
receptor
•Has anti-estrogenic effects on breast tissue.
•The ability to produce both estrogenic and anti-estrogenic affects is most likely
due to the interaction with other coactivators or corepressors in the tissue and
the binding with different estrogen receptors, ER and ER
•Subsequent to tamoxifen ER binding, the expression of estrogen dependent
genes is blocked or altered
•Resulting in decreased estrogen response.
•Most of tamoxifen’s affects occur in the G1 phase of the cell cycle
101By: Dharmendrasinh Baria

102. Therapeutic UsesTherapeutic Uses
•Tamoxifen can be used as primary therapy for metastatic breast
cancer in both men and postmenopausal women
•Patients with estrogen-receptor (ER) positive tumors are more likely
to respond to tamoxifen therapy, while the use of tamoxifen in
women with ER negative tumors is still investigational
•When used prophylactically, tamoxifen has been shown to decrease
the incidence of breast cancer in women who are at high risk for
developing the disease
102By: Dharmendrasinh Baria

103. 4. Selective estrogen receptor down regulators- Fulvestrant
•Pure estrogen antagonist
•Uses: Metastatic ER+ Breast Cancer in postmenopausal women
•MOA:
•Inhibits ER dimerization & prevents interaction of ER with DNA
•ER is down regulated resulting in more complete supression of
ER responsive gene function.
103By: Dharmendrasinh Baria

104. 5. Aromatase Inhibitors
•Aromatase is the enzyme responsible for conversion of androstenedione
(androgen precursor) to estrone (estrogenic hormone).
- 1
st
gen.- Aminoglutethimide
- 2
nd
gen.- Formestane, Fadrozole, Rogletimide
- 3
rd
gen.- Exemestane, Letrozole,Anastrozole
oAromatase inhibitors (AIs) are a class of drugs used in the treatment of
breast cancer and ovarian cancer in postmenopausal women.
oAs breast and ovarian cancers require estrogen to grow, Aromatase
inhibitors are taken to either block the production of estrogen or block the
action of estrogen on receptors.
104By: Dharmendrasinh Baria

105. •Aminogluthethimide-Aminogluthethimide-
Mechanism of Action:
•Inhibitor of adrenal steroid synthesis at the first step, conversion of
cholesterol of pregnenolone.
•Inhibits the extra-adrenal synthesis of estrone and estradiol.
•Inhibits the enzyme aromatase that converts androstenedione to
estrone.
•ADR: Dizziness, Lethargy, Visual blurring, Rash
Therapeutic Uses: ER- and PR-positive metastatic breast cancer
105By: Dharmendrasinh Baria

106. 106By: Dharmendrasinh Baria

107. 6. Antiandrogens – Flutamide, Bicalutamide
•Antiandrogens, or androgen antagonists, first discovered in the
1960s, prevent androgens from expressing their biological effects on
responsive tissues.
•Antiandrogens alter the androgen pathway by blocking the
appropriate receptors, competing for binding sites on the cell's
surface, or affecting androgen production.
•Antiandrogens are most frequently used to treat prostate cancer.
107By: Dharmendrasinh Baria

108. 7. 5-α reductase Inhibitors – Finasteride, Dutasteride
108By: Dharmendrasinh Baria

109. 8. GnRH analogues – Nafarelin, Leuprorelin, triptorelin
•NAFERELIN : nasal spray / SC inj
•↓FSH & LH release from pituitary- ↓ the release of estrogen &
testosterone.
•USE : Breast Ca, Prostatic Cancer
9. Progestins: Medroxyprogesterone acetate, hydroxyprogesterone
caproate and megestrol
•2
nd
line hormonal therapy for metastatic hormone dependent breast ca
and endometrial cancer.
•Hydroxyprogesterone – used in metastatic endometrial Cancer.
•A/E: bleeding
109By: Dharmendrasinh Baria

110. 10. GnRH antagonists – Cetorelix, Ganirelix, Abarelix
•Cetrorelix, ganirelix and abarelix are antagonist of GnRH decrease the
release of gonadotropins without causing initial stimulation can be used
in prostatic ca without the risk of flare up reaction.
110By: Dharmendrasinh Baria

111. ClCH
2
CH
2
Cl NH
3
Ca(OH)
2
DMF
N
(C
2
H
5
)
3
N
PSCl
3
N
NPN
S
+
H
Thiotepa
O
NH
2
OH
NH
P
O
N
O
CH
2
CH
2
Cl
CH
2
CH
2
Cl
PO N
Cl
CH
2
CH
2
Cl
CH
2
CH
2
Cl
+
Propanolamine
bis-(2-chloroethylphosphoramide)
Cyclophosphamide
111By: Dharmendrasinh Baria

112. N
N NH
2
NH
2
NH
2
NH
2
BrCH
2
CH-C-H H
3
C-NH-
NH
CH-COONa
CH
2
CH
2
COONa
N
N N
N
NH
2
NH
2
CH
2
CH
3
NH
CH-COONa
CH
2
CH
2
COONa
AcOH
NaOH
I
2
/KI
+
Br
O
C
O
+
N C
O
2,4,5,6-tetramino pyrimidine 2,3- dibromopropioaldehyde
disodium p-(methyl-amibenzoyl)
glutamate
Methotrexate
112By: Dharmendrasinh Baria

113. C
2
H
5
S
NH
2
HBr
NH
EtO-C
HKO
F
O
N
N
F
O
C
2
H
5
S
NH
N
F
O
O
H
NH
N
F
O
O
H
H
CF
3
OF
CFCl
3
C +
+
S-Ethylisothiouranium bromide
K salts of ethyl 2 fluoro-2-formylacetate
uracil
fluorooxy trifluromethane
5-fluorouracil
113By: Dharmendrasinh Baria

114. 1.Antineoplastic agents, J.H Block & J.M Beale., Wilson & Giswold’s
Textbook of Organic Medicinal Chemistry & pharmaceutical
chemistry 12
th
Edition, 2011, pg. No. 355-412.
2.Tripathi KD, Anticancer drugs , Chemotherapy of neoplastic
diseases; 7th ed ; 857-877.
3.Foye’s Principles of medicinal chemistry, Sixth Edition, Thomas L.
Lemke, David A. Williams.
114By: Dharmendrasinh Baria

115. 115By: Dharmendrasinh Baria